FDA approves Alvotech and Teva Pharmaceuticals’ SELARSDI as biosimilar to Stelara

FDA approves Alvotech and Teva Pharmaceuticals’ SELARSDI as biosimilar to Stelara

In a significant development in the pharmaceutical industry, Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have announced the approval of SELARSDI (ustekinumab-aekn) injection by the U.S. Food and Drug Administration (FDA). This approval marks SELARSDI as a biosimilar to Stelara, designed for the treatment […]

Biocon Biologics secures license agreement for biosimilar launch in US

Biocon Biologics secures license agreement for biosimilar launch in US

In a landmark announcement, Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, revealed its settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson. This agreement signifies a crucial step forward, granting Biocon Biologics the license to commercialize its Bmab 1200, a proposed biosimilar to […]